Logo image of KALV

KALVISTA PHARMACEUTICALS INC (KALV) Stock Fundamental Analysis

NASDAQ:KALV - Nasdaq - US4834971032 - Common Stock - Currency: USD

11.92  -0.06 (-0.5%)

After market: 11.92 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to KALV. KALV was compared to 572 industry peers in the Biotechnology industry. KALV has a great financial health rating, but its profitability evaluates not so good. KALV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KALV has reported negative net income.
KALV had a negative operating cash flow in the past year.
KALV had negative earnings in each of the past 5 years.
KALV had a negative operating cash flow in each of the past 5 years.
KALV Yearly Net Income VS EBIT VS OCF VS FCFKALV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M

1.2 Ratios

KALV's Return On Assets of -97.24% is on the low side compared to the rest of the industry. KALV is outperformed by 74.13% of its industry peers.
KALV has a Return On Equity (-116.71%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -97.24%
ROE -116.71%
ROIC N/A
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
KALV Yearly ROA, ROE, ROICKALV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K 1.5K

1.3 Margins

KALV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KALV Yearly Profit, Operating, Gross MarginsKALV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20K -40K -60K -80K

More info and screens

8

2. Health

2.1 Basic Checks

KALV has more shares outstanding than it did 1 year ago.
The number of shares outstanding for KALV has been increased compared to 5 years ago.
There is no outstanding debt for KALV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KALV Yearly Shares OutstandingKALV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
KALV Yearly Total Debt VS Total AssetsKALV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

An Altman-Z score of 5.81 indicates that KALV is not in any danger for bankruptcy at the moment.
The Altman-Z score of KALV (5.81) is better than 82.17% of its industry peers.
KALV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 5.81
ROIC/WACCN/A
WACCN/A
KALV Yearly LT Debt VS Equity VS FCFKALV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

KALV has a Current Ratio of 6.87. This indicates that KALV is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.87, KALV is in the better half of the industry, outperforming 67.13% of the companies in the same industry.
A Quick Ratio of 6.87 indicates that KALV has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.87, KALV is doing good in the industry, outperforming 67.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.87
Quick Ratio 6.87
KALV Yearly Current Assets VS Current LiabilitesKALV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for KALV have decreased strongly by -18.95% in the last year.
EPS 1Y (TTM)-18.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.75%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KALV will show a very strong growth in Earnings Per Share. The EPS will grow by 21.76% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.43%
EPS Next 2Y7.94%
EPS Next 3Y17.99%
EPS Next 5Y21.76%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KALV Yearly Revenue VS EstimatesKALV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M 400M 500M
KALV Yearly EPS VS EstimatesKALV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KALV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year KALV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KALV Price Earnings VS Forward Price EarningsKALV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KALV Per share dataKALV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

KALV's earnings are expected to grow with 17.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.94%
EPS Next 3Y17.99%

More info and screens

0

5. Dividend

5.1 Amount

KALV does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KALVISTA PHARMACEUTICALS INC

NASDAQ:KALV (3/7/2025, 8:00:02 PM)

After market: 11.92 0 (0%)

11.92

-0.06 (-0.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)12-05 2024-12-05/bmo
Earnings (Next)03-12 2025-03-12/bmo
Inst Owners104.63%
Inst Owner Change17.07%
Ins Owners1.51%
Ins Owner Change6.31%
Market Cap589.09M
Analysts86.25
Price Target27.43 (130.12%)
Short Float %13.32%
Short Ratio14.76
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.21%
Min EPS beat(2)1.74%
Max EPS beat(2)6.68%
EPS beat(4)2
Avg EPS beat(4)-8.9%
Min EPS beat(4)-36.67%
Max EPS beat(4)6.68%
EPS beat(8)6
Avg EPS beat(8)3.13%
EPS beat(12)10
Avg EPS beat(12)5.59%
EPS beat(16)13
Avg EPS beat(16)4.57%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.54%
PT rev (3m)-7.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-74.8%
EPS NY rev (1m)0%
EPS NY rev (3m)-23.07%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.4
P/tB 4.4
EV/EBITDA N/A
EPS(TTM)-3.64
EYN/A
EPS(NY)-2.84
Fwd EYN/A
FCF(TTM)-2.49
FCFYN/A
OCF(TTM)-2.48
OCFYN/A
SpS0
BVpS2.71
TBVpS2.71
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -97.24%
ROE -116.71%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-48.3%
ROA(5y)-38.68%
ROE(3y)-54.5%
ROE(5y)-43.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 59.18%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.87
Quick Ratio 6.87
Altman-Z 5.81
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)129.01%
Cap/Depr(5y)89%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-13.75%
EPS Next Y-9.43%
EPS Next 2Y7.94%
EPS Next 3Y17.99%
EPS Next 5Y21.76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-46.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-46.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-43.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-45.55%
OCF growth 3YN/A
OCF growth 5YN/A